Khiron Eyes $44 Billion Dermatological Drug Market

As part of an agreement with Centro Dermatológico Federico Lleras Acosta (CDFLLA), Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) presented its cannabis dermatological research at II TeraCILAD in Colombia, a medical conference attended by more than 1,000 dermatologists.

Story continues below

The research marks important progress towards the identification and validation of cannabis as a potential therapy for certain medical skin conditions, Khiron said in a statement.

The clinical evaluations are designed to identify the effectiveness of cannabanoids (CBD) in modulating inflammatory responses in certain melanoma cells and in keratinocytes, whose primary function is to form a barrier against environmental damage, with the possibility to establish potential therapeutic uses in some dermatological conditions.

Skin conditions continue to rise globally with the incidences of melanoma doubling in the past three decades to 287,723 new cases diagnosed and 60,712 deaths, according to Globocon cancer research laboratory.

Clinical research by Khiron and CDFLLA is expected to begin in the first quarter of 2020 and will be pursued subject to receipt of the government of Colombia permits.

CDFLLA is a university hospital that provides specialized dermatology outpatient services.

An ad to help with our costs